Alcohol Consumption Associated with Elevated Cancer Risk in Japan
Even in light to moderate levels, alcohol consumption appears to be associated with elevated cancer risks in Japan.
Related Articles
Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer
Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.
Selinexor Maintenance Improves PFS in TP53 Wild-Type Endometrial Cancer
The median PFS in patients with pMMR TP53 wild-type endometrial cancer was 39.5 months with selinexor and 4.9 months with placebo.
Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies
Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Renal Cell Carcinoma Treatment Algorithm
Rohit Gosain, MD; Rahul Gosain, MD; and Katy Beckermann, MD, PhD, discuss advances in renal cell carcinoma treatment, including adjuvant pembrolizumab following KEYNOTE-564 data, management…
Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.
EC Approved Liso-cel in Pretreated Relapsed/Refractory Follicular Lymphoma
Liso-cel has been approved by the European Commission for the treatment of adult patients with follicular lymphoma who received 2 or more prior lines of…
Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Afuresertib/Paclitaxel Shows No Survival Difference vs Paclitaxel in PROC
Although there was no statistical significance in survival data, afuresertib/paclitaxel improved PFS vs paclitaxel in patients with the pAKT biomarker.
Cadonilimab Combo Shows Encouraging Activity in Advanced Endometrial Cancer
Cadonilimab plus lenvatinib appeared to have a manageable safety profile in a phase 2 trial.